Mission
NMD Pharma is dedicated to developing novel treatments to improve muscle function and quality of life of patients with neuromuscular disease.
Vision
A future in which patients with neuromuscular disease live better and more independent lives.
We have a unique translational muscle electrophysiology platform leveraging in-depth know-how of muscle physiology and muscular disorders for discovering and developing first-in-class therapeutics in neuromuscular diseases with a significant unmet medical need.
NMD Pharma is the leading company utilizing ClC-1 Cl- ion channel inhibitors for neuromuscular diseases and currently has one clinical-stage product candidate for the treatment of myasthenia gravis.
We have more than 25 employees with expertise in all areas of drug development. We are headquartered in Aarhus, Denmark, and collaborate with internationally renowned companies and key opinion leaders in the field of neuromuscular diseases.
For more information, please visit the company website.
NMD Pharma is dedicated to developing novel treatments to improve muscle function and quality of life of patients with neuromuscular disease.
Vision
A future in which patients with neuromuscular disease live better and more independent lives.
We have a unique translational muscle electrophysiology platform leveraging in-depth know-how of muscle physiology and muscular disorders for discovering and developing first-in-class therapeutics in neuromuscular diseases with a significant unmet medical need.
NMD Pharma is the leading company utilizing ClC-1 Cl- ion channel inhibitors for neuromuscular diseases and currently has one clinical-stage product candidate for the treatment of myasthenia gravis.
We have more than 25 employees with expertise in all areas of drug development. We are headquartered in Aarhus, Denmark, and collaborate with internationally renowned companies and key opinion leaders in the field of neuromuscular diseases.
For more information, please visit the company website.
Location: Denmark, Aarhus
Employees: 11-50
Total raised: $121.42M
Founded date: 2015
Investors 1
| Date | Name | Website |
| 27.02.2022 | Jeito Capi... | jeito.life |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 17.11.2023 | Series B | $81.81M | - |
| 20.02.2022 | - | $39.61M | - |
Mentions in press and media 4
| Date | Title | Description |
| 17.11.2023 | Denmark-based NMD Pharma raises EUR 75 million in Series B funding | Denmark-based clinical-stage biotech dedicated to developing novel and improved treatments for patients living with neuromuscular diseases, NMD Pharma raised EUR 75 million in Series B financing. The round took place on November 16, 2023. C... |
| 16.11.2023 | NMD Pharma Raises €75M in Series B Financing | NMD Pharma, an Aarhus, Denmark-based clinical-stage biotechnology company for neuromuscular diseases, raised €75M in Series B funding. The round was led by Jeito Capital and included investments from other current investors Novo Holdings, L... |
| 20.02.2022 | NMD Pharma Raises €35M Financing | NMD Pharma, an Aarhus, Denmark-based clinical stage biotech company, raised €35M in funding. The round was led by Jeito Capital with participation from INKEF Capital, Novo Holdings, Roche Venture Fund and Lundbeck Foundation. Jeito Capital ... |
| - | NMD Pharma | “NMD Pharma” |